title: Implications of the SILCAAT and ESPRIT trials and the future for HIV immunotherapy.
authors.affiliation: Kings College London. Barry.Peters@kcl.ac.uk
authors.forename: Barry S
authors.initials: BS
authors.lastname: Peters
authors.forename: Miriam
authors.initials: M
authors.lastname: Samuel
mesh_terms: D016915:AIDS Vaccines / Q000627:therapeutic use; D019380:Anti-HIV Agents / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D015658:HIV Infections / Q000628:therapy*; D006801:Humans; D007167:Immunotherapy; D007376:Interleukin-2 / Q000031:analogs & derivatives / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D016915:AIDS Vaccines; D019380:Anti-HIV Agents; D007376:Interleukin-2; D011994:Recombinant Proteins; C082598:aldesleukin